863015-77-4Relevant academic research and scientific papers
Factor Xa inhibitors
-
Page/Page column 11, (2010/11/25)
The invention is concerned with novel heteroaryl fused cyclic amines of formula (I) wherein A, X1 to X3, Y1 to Y3, Z, R1, R2, m and n are as defined in the description and in the claims, as
Factor Xa inhibitors
-
Page/Page column 11, (2010/11/26)
The invention is concerned with novel cycloalkane carboxamides of formula (I) wherein X, X1, Y, Y1, R1′, R1″, R2, R3, m and n are as defined in the description and in the claims, as well as
A versatile copper-catalyzed coupling reaction of pyridin-2(1H)-ones with aryl halides
Filipski, Kevin J.,Kohrt, Jeffrey T.,Casimiro-Garcia, Agustin,Van Huis, Chad A.,Dudley, Danette A.,Cody, Wayne L.,Bigge, Christopher F.,Desiraju, Shrilakshmi,Sun, Shaoyi,Maiti, Samarendra N.,Jaber, Mohamad R.,Edmunds, Jeremy J.
, p. 7677 - 7680 (2007/10/03)
A robust method has been developed to couple a wide variety of pyridin-2-ones and aryl halides. This C-N bond forming reaction makes use of catalytic copper(I) iodide and the ligand 8-hydroxyquinoline. These conditions tolerate a wide degree of functional
Cyclic amines
-
Page/Page column 38, (2010/11/24)
The invention is concerned with cyclic amines of formula (I) wherein X1 to X3, Y1 to Y3, R1′, R1″ and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit coagulation factor Xa and can be used as medicaments and for treating diseases associated with coagulation factor Xa.
Beta-aminoacid-derivatives as factor Xa inhibitors
-
, (2008/06/13)
The present invention relates to compounds of the formula I, in which R0 ; R1 ; R2 ; R3 ; R4; R5, R6, Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
